Cargando…

What did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future?

A State of the Art lecture titled “What the direct oral anticoagulants (DOACs) trials did and didn’t tell us” was presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in 2022. The use of DOACs in children is of particular interest as they exhibit several advantages ov...

Descripción completa

Detalles Bibliográficos
Autores principales: Betensky, Marisol, Monagle, Paul, Male, Christoph, Goldenberg, Neil A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165148/
https://www.ncbi.nlm.nih.gov/pubmed/37168398
http://dx.doi.org/10.1016/j.rpth.2023.100140
_version_ 1785038209151926272
author Betensky, Marisol
Monagle, Paul
Male, Christoph
Goldenberg, Neil A.
author_facet Betensky, Marisol
Monagle, Paul
Male, Christoph
Goldenberg, Neil A.
author_sort Betensky, Marisol
collection PubMed
description A State of the Art lecture titled “What the direct oral anticoagulants (DOACs) trials did and didn’t tell us” was presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in 2022. The use of DOACs in children is of particular interest as they exhibit several advantages over conventional anticoagulation agents most commonly used in pediatrics. To date, several DOAC pediatric investigational programs (PIPs) have been completed, and although they have provided some of the best quality of evidence in pediatric anticoagulation therapy, the data generated by these trials remain limited. Here, we review and summarize the currently available data provided by the DOAC PIPs, provide perspectives on what we have and have not learned from these trials, and how we might leverage this knowledge to optimize the design of future anticoagulant PIPs. Finally, we summarize relevant new data on this topic presented during the 2022 ISTH Congress.
format Online
Article
Text
id pubmed-10165148
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101651482023-05-09 What did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future? Betensky, Marisol Monagle, Paul Male, Christoph Goldenberg, Neil A. Res Pract Thromb Haemost State of the Art ISTH 2022 A State of the Art lecture titled “What the direct oral anticoagulants (DOACs) trials did and didn’t tell us” was presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in 2022. The use of DOACs in children is of particular interest as they exhibit several advantages over conventional anticoagulation agents most commonly used in pediatrics. To date, several DOAC pediatric investigational programs (PIPs) have been completed, and although they have provided some of the best quality of evidence in pediatric anticoagulation therapy, the data generated by these trials remain limited. Here, we review and summarize the currently available data provided by the DOAC PIPs, provide perspectives on what we have and have not learned from these trials, and how we might leverage this knowledge to optimize the design of future anticoagulant PIPs. Finally, we summarize relevant new data on this topic presented during the 2022 ISTH Congress. Elsevier 2023-03-30 /pmc/articles/PMC10165148/ /pubmed/37168398 http://dx.doi.org/10.1016/j.rpth.2023.100140 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle State of the Art ISTH 2022
Betensky, Marisol
Monagle, Paul
Male, Christoph
Goldenberg, Neil A.
What did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future?
title What did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future?
title_full What did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future?
title_fullStr What did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future?
title_full_unstemmed What did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future?
title_short What did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future?
title_sort what did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future?
topic State of the Art ISTH 2022
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165148/
https://www.ncbi.nlm.nih.gov/pubmed/37168398
http://dx.doi.org/10.1016/j.rpth.2023.100140
work_keys_str_mv AT betenskymarisol whatdidwelearnanddidnotlearnfromthepediatricdirectoralanticoagulanttrialsandhowmightwebetterdesignpediatricanticoagulanttrialsinthefuture
AT monaglepaul whatdidwelearnanddidnotlearnfromthepediatricdirectoralanticoagulanttrialsandhowmightwebetterdesignpediatricanticoagulanttrialsinthefuture
AT malechristoph whatdidwelearnanddidnotlearnfromthepediatricdirectoralanticoagulanttrialsandhowmightwebetterdesignpediatricanticoagulanttrialsinthefuture
AT goldenbergneila whatdidwelearnanddidnotlearnfromthepediatricdirectoralanticoagulanttrialsandhowmightwebetterdesignpediatricanticoagulanttrialsinthefuture